AstraZeneca PLC [AZN] Is Currently 1.30 below its 200 Period Moving Avg: What Does This Mean?

AstraZeneca PLC [NASDAQ: AZN] price surged by 1.30 percent to reach at $0.72. The company report on October 24, 2022 that IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Approval based on HIMALAYA Phase III trial results which showed single priming dose of IMJUDO added to IMFINZI reduced risk of death by 22% vs. sorafenib.

AstraZeneca’s IMJUDO® (tremelimumab) in combination with IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. The novel dose and schedule of the combination, which includes a single dose of the anti-CTLA-4 antibody IMJUDO 300mg added to the anti-PD-L1 antibody IMFINZI 1500mg followed by IMFINZI every four weeks, is called the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab).

A sum of 5838304 shares traded at recent session while its average daily volume was at 6.58M shares. AstraZeneca PLC shares reached a high of $56.22 and dropped to a low of $55.50 until finishing in the latest session at $55.90.

The one-year AZN stock forecast points to a potential upside of 22.25. The average equity rating for AZN stock is currently 1.80, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on AstraZeneca PLC [AZN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $71.90 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Credit Suisse have made an estimate for AstraZeneca PLC shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 15, 2022. The new note on the price target was released on September 07, 2022, representing the official price target for AstraZeneca PLC stock. Previously, the target price had yet another raise to $75, while Argus analysts kept a Buy rating on AZN stock.

The Average True Range (ATR) for AstraZeneca PLC is set at 1.30, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 3.87. The Price to Book ratio for the last quarter was 4.82, with the Price to Cash per share for the same quarter was set at 1.60. Price to Free Cash Flow for AZN in the course of the last twelve months was 77.42 with Quick ratio for the last quarter at 0.70.

AZN Stock Performance Analysis:

AstraZeneca PLC [AZN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.13. With this latest performance, AZN shares gained by 5.43% in over the last four-week period, additionally sinking by -14.08% over the last 6 months – not to mention a drop of -9.50% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 48.06, with the RSI for the last a single of trading hit 53.49, and the three-weeks RSI is set at 45.01 for AstraZeneca PLC [AZN]. The present Moving Average for the last 50 days of trading for this stock 58.98, while it was recorded at 54.98 for the last single week of trading, and 62.50 for the last 200 days.

Insight into AstraZeneca PLC Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and AstraZeneca PLC [AZN] shares currently have an operating margin of +7.57 and a Gross Margin at +60.90. AstraZeneca PLC’s Net Margin is presently recorded at +0.30.

Return on Total Capital for AZN is now 5.33, given the latest momentum, and Return on Invested Capital for the company is 0.22. Return on Equity for this stock inclined to 0.40, with Return on Assets sitting at 0.13. When it comes to the capital structure of this company, AstraZeneca PLC [AZN] has a Total Debt to Total Equity ratio set at 78.39. Additionally, AZN Total Debt to Total Capital is recorded at 43.94, with Total Debt to Total Assets ending up at 29.21. Long-Term Debt to Equity for the company is recorded at 73.57, with the Long-Term Debt to Total Capital now at 41.24.

Reflecting on the efficiency of the workforce at the company, AstraZeneca PLC [AZN] managed to generate an average of $980 per employee. Receivables Turnover for the company is 5.18 with a Total Asset Turnover recorded at a value of 0.43.AstraZeneca PLC’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 1.00.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AstraZeneca PLC go to 14.80%.

AstraZeneca PLC [AZN] Insider Position Details

There are presently around $30,002 million, or 18.50% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 85,919,796, which is approximately -8.819% of the company’s market cap and around 0.50% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 48,297,922 shares of the stock with an approximate value of $2.7 billion in AZN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $2.56 billion in AZN stock with ownership of nearly -1.088% of the company’s market capitalization.

Positions in AstraZeneca PLC stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 432 institutional holders increased their position in AstraZeneca PLC [NASDAQ:AZN] by around 61,354,479 shares. Additionally, 429 investors decreased positions by around 33,015,624 shares, while 211 investors held positions by with 442,334,856 shares. The mentioned changes placed institutional holdings at 536,704,959 shares, according to the latest SEC report filing. AZN stock had 103 new institutional investments in for a total of 9,478,941 shares, while 86 institutional investors sold positions of 3,868,858 shares during the same period.


Please enter your comment!
Please enter your name here